OneRF ablation system gets ICD-10-PCS CMS procedure code
Hospitals can report procedures using the system starting Oct. 1
NeuroOne Medical Technologies said the Centers for Medicare and Medicaid Services (CMS) granted a new ICD-10-PCS code to its OneRF Ablation procedure, a development the company said will lead to greater use of the technology.
Effective Oct. 1, hospitals will be allowed to report inpatient procedures performed with the system, which is designed to remove selected regions of brain tissue as a way of treating neurological conditions like Parkinson’s disease.
“We are pleased that CMS has provided an ICD-10-PCS code that describes our OneRF procedure, which we believe will drive better recognition of our technology and greater utilization within the healthcare system,” Dave Rosa, NeuroOne’s CEO, said in a company press release. “In our view, CMS approval of our new code is a critical step in facilitating broader market acceptance of our technology’s potential to reduce hospital stays, numbers of surgeries, and adverse events, while offering enhanced patient safety.”
The code assignment follows U.S. Food and Drug Administration (FDA) clearance of the company’s application to market the system. NeuroOne began a limited launch of the product earlier this year.
Removing brain tissue to ease tremors
Removing small and specific areas of brain tissue can control certain motor symptoms in people with Parkinson’s disease, according to NeuroOne. Tissue ablation in a brain region called the thalamus may ease tremors, while ablation in the globus pallidus interna could reduce muscle stiffness and uncontrolled movements.
Radiofrequency ablation uses radio waves to heat and kill cells in targeted sections of brain tissue. The OneRF system uses NeuroOne’s Evo stereoelectroencephalography electrodes, a set of thin and flexible electrodes implanted close to the brain.
Electroencephalogram, or EEG, technology is used to measure electrical activity in the brain, helping to identify abnormalities that are indicative of Parkinson’s or other neurological diseases. NeuroOne says its Evo sEEG system uses electrodes that are thinner and more flexible than other systems, and may offer better signal clarity than other devices on the market.
The EVO system was approved by the FDA in 2022 for use up to 30 days.
About the Author
